20 October 2021 - The second approval for zanubrutinib this month.

The TGA has approved zanubrutinib (Brukinsa) for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy.

Read Australian prescription medicine decision summary for zanubrutinib